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Major Bleeding Complications and Persistence With Oral
Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary
Findings in Real-Life Danish Patients
Morten Lamberts, MD, PhD; Laila Staerk, MD; Jonas Bjerring Olesen, MD, PhD; Emil Loldrup Fosbøl, MD, PhD; Morten Lock Hansen, MD,
PhD; Louise Harboe; Cinira Lefevre, PhD; David Evans, MBBS, PhD; Gunnar Hilmar Gislason, MD, PhD
Background-—The nonvitamin K antagonist oral anticoagulants have recently become available as an alternative to warfarin as
stroke prophylaxis in atrial ﬁbrillation, but data on real-life patient experience, including bleeding risk, are lacking. Our objective
was to compare major bleeding events and nonpersistence between the nonvitamin K antagonist oral anticoagulant apixaban and
other nonvitamin K antagonist oral anticoagulants (dabigatran and rivaroxaban) and warfarin in a contemporary, nation-wide cohort
of patients with nonvalvular atrial ﬁbrillation.
Methods and Results-—Of 54 321 patients (median age, 73 years; 56% male; mean CHA2DS2-VASc score, 2.9), 7963, 6715,
15 413, and 24 230 patients initiated apixaban, rivaroxaban, dabigatran, and warfarin, respectively. Apixaban and rivaroxaban
initiators were older, less often male, with higher HAS-BLED and CHA2DS2-VASc scores compared with dabigatran and warfarin
initiators. A total of 2418 patients (4.5%) experienced a major bleeding event over all available follow-up. In this period, rivaroxaban
(hazard ratio [HR] [95% CI], 1.49 [1.27–1.77]), dabigatran (HR, 1.17 [1.00–1.38]), and warfarin (HR, 1.23 [1.05–1.43]) users were
signiﬁcantly more likely to bleed than apixaban users. Findings were similar when restricted to the ﬁrst 30 days after OAC
initiation. Risk of nonpersistence was higher for dabigatran (HR, 1.45 [1.33–1.59]) and warfarin initiators (HR, 1.22 [1.12–1.33]),
but not for rivaroxaban initiators (HR, 1.07 [0.96–1.20]) compared with apixaban initiators.
Conclusions-—In a real-world cohort of nonvalvular atrial ﬁbrillation patients, apixaban had a lower adjusted major bleeding risk
compared with rivaroxaban, dabigatran, and warfarin. Apixaban had a lower risk of nonpersistence compared with dabigatran and
warfarin and similar risk compared with rivaroxaban. ( J Am Heart Assoc. 2017;6:e004517. DOI: 10.1161/JAHA.116.004517.)
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N onvitamin K antagonist oral anticoagulants (NOACs)may have a large impact on standard stroke preven-
tion and management in atrial ﬁbrillation (AF). Predictable
pharmacodynamics and kinetics with fewer drug-drug and
drug-food interactions compared with warfarin may simplify
their use for health care professionals and patients. Several
major trials have shown on-par or better efﬁcacy and safety
compared with warfarin.1–3 In these trials, apixaban and low-
dose dabigatran had lower risk of major bleeding compared
with warfarin, whereas the risk was similar for rivaroxaban
and high-dose dabigatran against warfarin. Despite consid-
erable interest in the NOACs in recent years, data about
their use and performance in real-life clinical care are
limited. In particular, there is a need for safety data looking
at any differences in bleeding risk and persistence between
NOACs in routine care. Also, whereas previous studies
suggest an initially increased bleeding risk with use of
warfarin, it is unknown whether this should be a concern
when initiating an NOAC.4
European and American guidelines now support NOACs as
an option in ﬁrst-line oral anticoagulant (OAC) therapy for
patients with nonvalvular AF with 1 or more stroke risk
factors.5,6 However, transition from randomized evidence to
actual clinical practice is key to optimize the management of
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OAC drug use in patients with AF. Data from Danish
administrative registries provide comprehensive data on
actual clinical practice and patient outcomes. We therefore
aimed to assess and compare shorter-term (within 30 days)
and longer-term major bleeding events and persistence
comparing apixaban, rivaroxaban, dabigatran, and warfarin
using Danish data sets.
Methods
Registries
From nation-wide administrative registries, we extracted
information on hospitalizations, vital status, and pharmaco-
logical treatment for each patient using a personal and
unique identiﬁer.7 The National Patient Registry contains
information on hospital discharge codes with both primary
and secondary diagnoses. Diagnoses are recorded by the
International Classiﬁcation of Diseases (ICD) 8th (until 1994)
and 10th revisions (from 1995 and onward). The registry also
holds information on surgical procedures according to the
NOMESCO classiﬁcation.7 The National Prescription Registry
includes information on prescription drugs in terms of
strength, number of tablets, and date of prescription
according to Anatomical Therapeutical Classiﬁcation codes.8
The Civil Personal Registry holds information on vital status,
sex, and age.9 We use cross-linkage through secured servers
to link patients, hospitalization diagnoses, and prescription
information at the individual level over time. All registries
included information up to December 31, 2015. Codes used
are in Table 1.
Study Population and OAC Treatment
We identiﬁed all patients aged 18 years or older with a history
of nonvalvular AF and grouped them into 4 cohorts according
to the ﬁrst OAC (apixaban, rivaroxaban, dabigatran, and
warfarin) initiated in the study period (August 22, 2011 to
December 31, 2015; Figure 1). We deﬁned new initiation as
no OAC prescription 6 months before inclusion; hence, the
population consisted of “na€ıve” OAC users.10 Date of ﬁrst
prescription claim deﬁned the date of inclusion. We only
included dosages recommended and approved by the Danish
Health and Medicines Authority for thromboprophylaxis in AF
(apixaban 2.5 and 5 mg twice-daily [BID; approved December
10, 2012], dabigatran 110 and 150 mg BID [approved August
22, 2011], and rivaroxaban 15 and 20 mg once-daily (OD;
approved February 6, 2012]). We excluded patients with
recent (<6 months) venous thromboembolism or pulmonary
embolism or recent (<5 weeks) hip or knee prosthetic
implantation surgery to ensure patients received OAC treat-
ment for AF.
We deﬁned exposure periods to the different OAC treat-
ments during follow-up using all prescription claims during the
study period. Patients were considered exposed to a speciﬁc
OAC when tablets were available for consumption. The
algorithm to calculate this, as previously published, uses the
date, number, and strength of tablets claimed for each
individual from the national prescription registry.11 If hospi-
talization occurs, no consumption of tablets was recorded
given that hospitals deliver medication during hospital stays.
Exposure to more than 1 OAC was not allowed, so any
subsequent prescription claim for a different OAC deﬁned
treatment switch. Patients could stop or switch OAC treat-
ment during follow-up according to availability of tablets (for
deﬁnition of duration of exposure, please see below). The
NOAC, edoxaban, was not available in Denmark in the study
period.
Comorbidity and Concomitant Pharmacotherapy
Stroke risk factors comprising the CHA2DS2-VASc (congestive
heart failure, hypertension, age >75 years, diabetes mellitus,
stroke/transitional cerebral ischemia, vascular disease, age
65–74 year, or female sex) score were deﬁned from the
registries as previously published.12 The score has been
shown to accurately predict risk of stroke in a similar
population with AF. Bleeding risk factors comprising a
modiﬁed HAS-BLED (hypertension, abnormal renal or liver
function, stroke, bleeding, labile international normalized ratio
[INR], elderly [>65 years], drugs [nonsteroidal anti-inﬂamma-
tory drug {NSAID}, antiplatelets, alcohol]) score were deﬁned
in a similar manner.13 Labile INR was not included because
INR values were not available. Antiplatelet treatment at
baseline was deﬁned by prescription of either aspirin and
nonaspirin (ie, clopidogrel, ticagrelor, and prasugrel) anti-
platelet agents in the 6 months preceding inclusion.
Major Bleeding Complications
We deﬁned major bleeding events as ﬁrst hospitalization
associated with a code for bleeding and reported bleeding
overall and by site, including gastrointestinal and intracranial
bleedings (Table 1). This deﬁnition includes all relevant
thrombolysis in myocardial infarction major bleeds14 and
has been used previously.11 We examined ﬁrst bleeding
events during the full follow-up time available in the registries
(“total bleeding”) and also restricted to the ﬁrst 30 days after
OAC initiation (“30-day bleeding”).
Persistence
We deﬁned nonpersistence as no claim for the same as well
as for any OAC for at least 30 days following the end of last
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Table 1. Codes Used
ICD/ATC/NOMESCO Codes Comment
Inclusion criteria
AF Presence of: ICD8: 42793, 42794. ICD10: I48.
Absence of: ICD8: 4240, 4241, 39500–39502, 39508,
39509, 39600–39604, 39608, 39609.
ICD10: I05, I06, I080A, I081A, I082A, I083A, Z952, Z954.
NCSP: KFKD, KFKH, KFMD, KFMH, KFGE, KFJF
Defined from diagnosis of AF with the absence of
diagnosis codes of valvular AF and mitral or aortic
valve surgery
OAC treatment ATC: B01AA03, B01AE07, B01AF01, B01AF02 Includes use of warfarin, apixaban, rivaroxaban, and
dabigatran
Exclusion criteria
Recent venous
thromboembolism
ICD-10: I801–3, I808–9, I821–3, I8289
Recent orthopedic
surgery
NOMESCO: KNFB, KNFC, KNGB, KNGC
Outcome
Major bleeding ICD-10: D62, I60, I61, I62, R31, R04, D500, H313, H356,
H431, H450, I312, I850, K250, K252, K254, K256, K260,
K262, K264, K266, K270, K272, K274, K276, K280,
K282, K284, K286, K625, K661, K920, K921, K922,
S064, S065, S066, J942, K228F, K298A, K638B, K638C,
K838F, K868G, I864A, H052A, S368D, G951A
Defined from diagnosis of intracranial bleeding, major
gastrointestinal bleeding, respiratory, renal/urinary
tract, ocular, retroperitoneal or pericardial bleeding,
and bleeding attributed to anemia. Only bleedings
requiring hospitalization were used
Comorbidity/medication
Hypertension ATC: C02A, C02B, C02C, C02L, C03A, C03B, C03D, C03E,
C03X, C07B, C07C, C07D, C08G, C02DA, C09BA, C09DA,
C02DB, C02DD, C02DG, C07A, C07B, C07C, C07D, C07F,
C08, C09BB, C09DB, C09AA, C09BA, C09BB, C09CA,
C09DA, C09DB, C09XA02, C09XA52
Defined from combination treatment with at least 2
classes of antihypertensive drugs: adrenergic a-
antagonists, nonloop diuretics, vasodilators, beta-
blockers, calcium-channel blockers, and renin-
angiotension system inhibitors
Stroke ICD-10: DI63, DI64, DI74, G458, G459 Includes transient ischemic attack
Vascular disease ICD-10: I21, I22, I700, I702, I703, I704, I705, I706, I707,
I708, I709
Includes myocardial infarction and peripheral artery
disease
Chronic kidney
disease
ICD-10: N02, N03, N04, N05, N06, N07, N08, N11, N12,
N14, N18, N19, N26, N158, N159, N160, N162, N163,
N164, N168, Q612, Q613, Q615, Q619, E102, E112,
E132, E142, I120, M300, M313, M319, M321B
Defined from diagnosis of chronic glomerulonephritis,
chronic tubulointestinal nephropathy, diabetic, and
hypertensive nephropathy among others
Liver disease ICD-10: B15, B16, B17, B18, B19, C22, K70, K71, K72,
K73, K74, K75, K76, K77, Z944, I982, D684C, Q618A
Defined from diagnosis of liver chronic liver disease,
cirrhosis, and hepatitis
Alcohol abuse ICD-10: F10, K70, E52, T51, K860, E244, G312, I426,
O354, Z714, Z721, G621, G721, K292, L278A, ATC:
N07BB
Defined from alcohol-related diagnosis codes or at least
1 dispensed prescription of an alcohol antagonist drug
used to treat chronic alcoholism
Bleeding ICD-10: D62, I60, I61, I62, R31, R04, D500, H313, H356,
H431, H450, I312, I850, K250, K252, K254, K256, K260,
K262, K264, K266, K270, K272, K274, K276, K280,
K282, K284, K286, K625, K661, K920, K921, K922,
S064, S065, S066, J942, K228F, K298A, K638B, K638C,
K838F, K868G, I864A, H052A, S368D, G951A
Heart failure ICD10: I42, I50, I110, J81
Diabetes mellitus ATC: A10 Codes for glucose-lowering medication
Aspirin ATC: B01AC06, N02BA01
Nonaspirin
antiplatelets
ATC: B01AC22, B01AC24, B01AC04 Includes clopidogrel, prasugrel, ticagrelor
NSAID ATC: M01A Excludes glucosamin (M01AX05)
AF indicates atrial ﬁbrillation; ICD, International Classiﬁcation of Diseases; NSAID, nonsteroidal anti-inﬂammatory drug; OAC, Oral anticoagulant.
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OAC treatment period (ie, a treatment gap of more than
30 days).
Statistical Analyses
For baseline characteristics, we described continuous vari-
ables by the mean and SD or median and interquartile range
(IQR). For the persistence analyses, we calculated the
duration of each OAC treatment period as the time from
inclusion date to nonpersistence date as deﬁned above (of
note and as described above—switch of treatment before
date of nonpersistence was allowed). For the bleeding
analyses, we calculated the duration from inclusion date to
ﬁrst bleeding event, censoring at date of nonpersistence. For
both sets of analyses, we also censored at date of claim for
more than 1 OAC drug (because there is no valid indication for
more than 1 concurrent OAC), death, and end of study.
Figure 2 illustrates allocation of major bleeding and nonper-
sistence outcome and switch of treatment according to OAC
exposure.
We estimated risk of major bleeding and of nonpersistence
by Cox regression models adjusted for age, sex, calendar
year, variables in the CHA2DS2-VASc and HAS-BLED scores,
and switch of OAC treatment. For all analyses, apixaban was
used as reference. For the primary outcomes, additional
analyses using warfarin as reference were conducted. We
calculated cumulative incidences of major bleeding and
nonpersistence (accounting for competing risks of death
and switching OAC) for the ﬁrst 3 years of follow-up. Because
of the time-varying OAC exposure, we only reported cumu-
lative incidence for patients’ ﬁrst OAC.
The only clinically relevant interactions found was sex, so
we undertook additional stratiﬁed analyses of major bleeding
(P for interaction, 0.0016) and nonpersistence (P for interac-
tion, <0.0001) by sex. For the nonpersistence outcome, the
initial risk would differ between warfarin/rivaroxaban and
apixaban/dabigatran, because typical warfarin and rivaroxa-
ban pack sizes last for 100 days, whereas shorter for
apixaban (50 days) and dabigatran (30 days), that is, the
initial length of exposure differed between OAC. Hence, we
performed a landmark analysis at the 90-day mark. No other
violation of model assumptions was found.
We ran the following preplanned, supplemental analyses:
(1) stratiﬁed dabigatran use by 110 and 150 mg BID patients
including an analysis for patients under the age of 80 years
only (ie, excluding patients where 150 mg of BID is not
indicated), given that different dosages were investigated
separately in the RE-LY trial; (2) major bleeding complications
and nonpersistence from when all NOACs were available
(January 1, 2013 [Deﬁned data of “Debut apixaban”]) to
minimize selection bias caused by change of NOAC availabil-
ity during follow-up; and (3) stratiﬁcation by to patients who
Figure 1. Overview of the study population. OAC indicates oral anticoagulant.
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did and who did not switch between OAC drugs given that
switchers may be a different population from nonswitchers.
All analyses used the SAS statistical package (version 9.4;
SAS Institute Inc., Cary, NC) and R (version 4.1; R Foundation
for Statistical Computing).
Ethics
This study was approved by the Danish Data Protection
Agency (reference no. 2007-58-0015; internal reference:
GEH-2014-013 I-suite no. 02731). Information was made
available to us by encrypted data access with anonymization
of patients so that no individuals could be identiﬁed. By
Danish law, retrospective studies do not require ethical
committee approval.
Results
Population and Follow-up
We identiﬁed 54 321 patients with nonvalvular AF who initiated
OAC treatment. Median age was 73 years (IQR, 66–81), 56%
were male, and mean CHA2DS2-VASc and HAS-BLED scores
were 2.9 (SD, 1.6) and 2.2 (SD, 1.2), respectively. Mean follow-
up time per patient was 403 days and total patient-time at-risk
was 67 764 person-years. Patient characteristics by OAC
initiated are in Table 2. Patients initiating apixaban and
rivaroxaban were older and less often male, with higher
CHA2DS2-VASc scores, compared with dabigatran or warfarin
users. According to year of inclusion, apixaban and rivaroxaban
initiation was more frequent at the end of the study period
whereas dabigatran and warfarin initiation declined. Charac-
teristics of dabigatran 110 and 150 mg BID initiators are in
Table 3. Dabigatran 110 mg BID users were considerably older
(mean age, 80.1 vs 65.6 years) with higher mean HAS-BLED
score (2.5 vs 1.8) compared to dabigatran 150 mg BID users.
Among warfarin initiators, 11.4% (n=2752) subsequently
switched to an NOAC (564 to apixaban, 758 to rivaroxaban,
and 1430 to dabigatran, comprising 20.5%, 27.5%, and 52.0%,
respectively). Among initiators of an NOAC, 9.4% (n=2070)
subsequently switched to warfarin. Switchers between speciﬁc
OAC treatments are shown in Table 4. Mean follow-up time
ranged from 268 to 511 days between OAC groups (Table 5).
Major Bleeding Complications
Of all included patients, 4.5% (2418) experienced a major
bleeding event during total follow-up. Most common bleeding
sites were gastrointestinal, renal, and intracranial (Table 6).
Crude incidence rates during follow-up were 3.6 (252 events),
4.3 (343 events), 2.9 (695 events), and 3.9 (1128 events) per
100 person-years for apixaban, rivaroxaban, dabigatran, and
warfarin, respectively. Figure 3 shows cumulative incidences
of major bleeding event by OAC initiated. Table 5 shows
adjusted risk of total and 30-day major bleeding for the
different OAC groups. Compared with apixaban, rivaroxaban,
dabigatran, and warfarin were all associated with increased
total and 30-day major bleeding risk. Compared with warfarin,
rivaroxaban was associated with a higher and apixaban with a
lower total major bleeding risk (hazard ratio [HR], 0.82 [0.70–
0.95]); dabigatran had a similar total major bleeding risk to
warfarin. The 30-day major bleeding risk was lower for
apixaban (HR, 0.71 [0.51–0.99]) compared to warfarin and
comparable for rivaroxaban (HR, 1.20 [0.90–1.60]) and
dabigatran (HR, 1.17 [0.93–1.47]). In the sex-stratiﬁed
analyses (Table 7), there was an increased total major
bleeding risk versus apixaban for rivaroxaban, but not for
dabigatran or warfarin, among men. There was an increased
total major bleeding risk for all OACs versus apixaban among
women.
Figure 2. Examples of allocation of major bleeding and nonpersistence outcome and switch of treatment
according to OAC exposure. OAC indicates oral anticoagulant.
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Nonpersistence
Of all included patients, 14 800 (27.2%) experienced a break
of at least 30 days during follow-up. Figure 4 shows the
cumulative incidence of nonpersistence by OAC initiated for
patients who did not switch OAC. After 3 years, 15% of
apixaban and rivaroxaban, 30% of dabigatran, and 60% of
warfarin patients were nonpersistent. In the adjusted analyses
with apixaban as reference, dabigatran or warfarin initiators
were more likely to be nonpersistent whereas rivaroxaban
initiators had similar risk (Table 5). In the adjusted analyses
with warfarin as reference, apixaban (HR, 0.82 [0.75–0.89])
Table 2. Characteristics of the Study Population
Apixaban Rivaroxaban Dabigatran Warfarin
No. of patients 7963 6715 15 413 24 230
Low dosage (%)/high dosage (%) 3010 (37.8)/4953 (62.2) 1840 (27.4)/4875 (72.6) 6234 (40.4)/9179 (59.6) N/A
Age, median [IQR] 76 [68, 84] 74 [67, 83] 71 [65, 79] 73 [65, 80]
Age, mean (SD) 75.4 (11.10) 74.4 (11.0) 71.5 (11.0) 72.1 (11.3)
Male sex (%) 4049 (50.8) 3490 (52.0) 8740 (56.7) 14 159 (58.4)
Year of inclusion (%)
2011 — — 1465 (9.5) 4481 (18.5)
2012 — 447 (6.7) 4506 (29.2) 6658 (27.5)
2013 632 (7.9) 1737 (25.9) 4596 (29.8) 5358 (22.1)
2014 2794 (35.1) 1662 (24.8) 3608 (23.4) 4263 (17.6)
2015 4537 (57.0) 2869 (42.7) 1238 (8.0) 3470 (14.3)
CHA2DS2-VASc score, mean (SD) 3.15 (1.62) 3.02 (1.62) 2.73 (1.60) 2.91 (1.66)
CHA2DS2-VASc score, median [IQR] 3 [2, 4] 3 [2, 4] 3 [2, 4] 3 [2, 4]
CHA2DS2-VASc score (%)
Low (score 0) 353 (4.4) 294 (4.4) 1162 (7.5) 1675 (6.9)
Intermediate (score 1) 923 (11.6) 938 (14.0) 2451 (15.9) 3363 (13.9)
High (score >1) 6687 (84.0) 5483 (81.7) 11 800 (76.6) 19 192 (79.2)
HAS-BLED score, mean (SD) 2.25 (1.20) 2.21 (1.16) 2.05 (1.17) 2.18 (1.22)
HAS-BLED score, median [IQR] 2 [1, 3] 2 [1, 3] 2 [1, 3] 2 [1, 3]
HAS-BLED score (%)
Low (score 0–1) 2273 (28.5) 1944 (29.0) 5115 (33.2) 7312 (30.2)
Intermediate (score 2) 2404 (30.2) 2129 (31.7) 4863 (31.6) 7178 (29.6)
High (score >2) 3286 (41.3) 2642 (39.3) 5435 (35.3) 9740 (40.2)
Stroke (%) 1692 (21.2) 1228 (18.3) 2451 (15.9) 3597 (14.8)
Vascular disease (%) 828 (10.4) 619 (9.2) 1426 (9.3) 3343 (13.8)
Liver disease (%) 115 (1.4) 88 (1.3) 166 (1.1) 390 (1.6)
Heart failure (%) 1362 (17.1) 1120 (16.7) 2442 (15.8) 5128 (21.2)
Diabetes mellitus (%) 1031 (12.9) 830 (12.4) 1785 (11.6) 3354 (13.8)
Hypertension (%) 3463 (43.5) 3092 (46.0) 6907 (44.8) 11 699 (48.3)
Kidney disease (%) 391 (4.9) 276 (4.1) 330 (2.1) 1860 (7.7)
Bleeding (%) 1159 (14.6) 811 (12.1) 1816 (11.8) 3261 (13.5)
Alcohol misuse (%) 287 (3.6) 227 (3.4) 522 (3.4) 753 (3.1)
Nonaspirin antiplatelets (%) 917 (11.5) 690 (10.3) 1274 (8.3) 2173 (9.0)
Aspirin antiplatelet (%) 2982 (37.4) 2697 (40.2) 6212 (40.3) 10 267 (42.4)
NSAIDs (%) 1119 (14.1) 951 (14.2) 2279 (14.8) 3379 (13.9)
IQR indicates interquartile range; N/A, not applicable; NSAIDs, nonsteroidal anti-inﬂammatory drugs.
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and rivaroxaban (HR, 0.88 [0.81–0.95]) had lower risk of
nonpersistence whereas dabigatran had a higher risk (HR,
1.19 [1.14–1.24]). Sex-stratiﬁed analyses are in Table 7. In
the landmark analyses of nonpersistence, dabigatran (HR,
1.57 [1.34–1.85]) had an increased risk, warfarin (HR, 0.31
[0.26–0.37]) a decreased risk, and rivaroxaban a similar risk
(HR, 1.01 [0.81–1.26]) compared with apixaban during the
ﬁrst 90 days of follow-up. After the ﬁrst 90 days of follow-up,
the risk of nonpersistence was increased for all OACs
compared with apixaban, that is, dabigatran (HR, 1.56
[1.41–1.74]), rivaroxaban (HR, 1.20 [1.05–1.36]), and warfarin
(HR, 1.76 [1.59–1.95]).
Supplementary Analyses
Compared with apixaban, we found similar 30-day and total
major bleeding risk for dabigatran 150 mg BID, but higher
major bleeding risk for dabigatran 110 mg BID (Table 3).
There were no differences in major bleeding risk with
dabigatran 150 mg or dabigatran 110 mg BID compared to
apixaban in patients aged <80 years. Findings (major bleeding
and nonpersistence) were similar to those in the main
analyses when restricted to the period with availability of all
NOACs and for OAC switch and nonswitch patients (Table 8).
Discussion
This study reports contemporary data on OAC use and safety
in real-life nonvalvular AF patients following the marketing of
NOACs apixaban, dabigatran, and rivaroxaban. We had 3 main
ﬁndings. First, apixaban and rivaroxaban initiators had a
different clinical proﬁle from dabigatran and warfarin initia-
tors, because they were older and less often male, with higher
CHA2DS2-VASc and HAS-BLED scores. Second, apixaban had
lower 30-day and total major bleeding risk compared with
rivaroxaban, dabigatran, and warfarin. Third, dabigatran and
warfarin users were at higher risk of nonpersistence com-
pared to apixaban users, whereas rivaroxaban users had
similar risk.
The 3 major trials, comparing NOACs with warfarin—
ARISTOTLE (apixaban), RE-LY (dabigatran), and ROCKET-AF
(rivaroxaban)—have resulted in grade 1 recommendations by
American and European cardiac societies.5,6 American guide-
lines recommend NOAC in patients with AF with at least 2
stroke risk factors whereas European Society of Cardiology
guidelines support NOAC use with 1 or more risk factors
(excluding female sex without other stroke risk factors).
Indirect comparisons of trial data showed no noteworthy
difference in efﬁcacy between NOACs, but a potentially lower
risk of major bleeding for apixaban.15,16
Overall, the rate of major bleeding events ranged from 2.9
to 4.3 per 100 person-years in our study. These are higher
than those reported in trial data (2.1–3.6%/year) and are
readily explained by inclusion of older and unselected patients
in this real-world setting. In addition, deﬁnitions of bleeding
were not identical, given that our study included only serious
bleeding requiring hospitalization whereas trial events were
adjudicated from clinical workup. Given that new agents are
approved beyond a controlled setting, the addition of real-
world complications should be appreciated because the
degree of clinically meaningful events from trials have been
recognized as a major limitation.17 Dabigatran had the lowest
major bleeding rate, whereas apixaban had a lower adjusted
risk of major bleeding (both total and within 30 days of
initiation) than rivaroxaban, dabigatran, and warfarin. A recent
Table 3. Patient Characteristics and Risk of Major Bleeding
According to Initial Dabigatran Dosage
Characteristics
Dabigatran
110 mg BID
(n=6234)
Dabigatran
150 mg BID
(n=9179)
Males, n (%) 2793 (44.8) 5947 (64.8)
Age, y
Mean (SD) 80.1 (8.1) 65.6 (8.6)
Median (IQR) 81 [76, 85] 67 [61, 72]
CHA2DS2-VASc score,
mean (SD)
3.7 (1.4) 2.1 (1.4)
CHA2DS2-VASc score,
median [IQR]
4 [3, 5] 2 [1, 3]
CHA2DS2-VASc score (%)
Low (score 0) 47 (0.8) 1115 (12.1)
Intermediate (score 1) 237 (3.8) 2214 (24.1)
High (score >1) 5950 (95.4) 5850 (63.7)
HAS-BLED score, mean
(SD)
2.48 (1.06) 1.76 (1.15)
HAS-BLED score, median
[IQR]
2 [2, 3] 2 [1, 3]
HAS-BLED score (%)
Low (score 0–1) 1181 (18.9) 3934 (42.9)
Intermediate (score 2) 1982 (31.8) 2881 (31.4)
High (score >2) 3071 (49.3) 2364 (25.8)
Major bleeding*
30-day major bleeding 1.62 [1.11–2.38] 1.53 [0.99–2.36]
Total follow-up 1.29 [1.09–1.52] 0.98 [0.81–1.20]
30-day major bleeding
(age <80 years)
0.89 [0.46–1.70] 1.26 [0.75–2.10]
Total follow-up
(age <80 years)
1.07 [0.82–1.38] 0.92 [0.73–1.17]
Nonpersistence*
Nonpersistence 1.23 [1.12–1.36] 1.65 [1.50–1.80]
BID indicates twice-daily; IQR, interquartile range.
*Presented as adjusted hazard ratio (apixaban is reference).
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post-hoc analysis of ROCKET-AF showed that rivaroxaban
users had signiﬁcantly higher risk of major and nonmajor
gastrointestinal bleeding compared with warfarin users (HR,
1.42), which support potential differences found between
apixaban and rivaroxaban in the present study.18 A study of
elderly Medicare beneﬁciaries found that dabigatran users
had increased gastrointestinal bleeding compared to warfarin
users, although overall major bleeding risk was similar.19 In
contrast to the clinical trials, we found the increased major
bleeding risk most pronounced for females taking dabigatran
and warfarin compared to apixaban. There was no difference
by sex in bleeding risk in the ARISTOTLE (apixaban) and
ROCKET-AF (rivaroxaban) trials; RE-LY did not report these
data. Although not supported by the pivotal trials, a meta-
analysis including 7 trials of NOACs concluded that women
have a higher bleeding risk than men in acute venous
thromboembolism treated by NOAC.20 Possible mechanisms
include differences in creatinine clearance, volume distribu-
tion, and drug uptake between men and women.21 Our ﬁnding
suggests a need for future investigations (preferably random-
ized) of sex-related differences in bleeding between OAC
drugs.
When separating dabigatran into 110 and 150 mg BID, we
conﬁrmed previous registry-based ﬁndings that lower-dose
dabigatran was associated with higher major bleeding risk
when compared to warfarin.22,23 This is in contrast to RE-LY
and partly in contrast to results from a Medicare claims
analysis.19 The latter study consisted of an elderly AF
population (aged >65 years) using the nontrial dosage of
dabigatran 75 mg BID and reported only gastrointestinal
(nonsigniﬁcant increase in bleeding with high-dose dabiga-
tran) and intracranial bleeding (nonsigniﬁcant increase in
Table 5. Risk of Major Bleeding and Nonpersistence
Apixaban Rivaroxaban Dabigatran Warfarin
Availability of follow-up, days
Mean (SD) 268.4 (220.1) 348.5 (324.1) 511.4 (438.0) 398.0 (374.6)
Median (IQR) 214 (85–397) 230 (89–549) 392 (119–821) 251 (129–564)
Population
(Total No. of
Events) No. Events HR [95% CI] No. Events HR [95% CI] No. Events HR [95% CI] No. Events HR [95% CI]
Major bleeding
Total
major
bleeding
54 321 (2418) 252 Reference 343 1.49 [1.27–1.77] 695 1.17 [1.00–1.38] 1128 1.23 [1.05–1.43]
30-day
major
bleeding
54 321 (448) 52 Reference 71 1.69 [1.18–2.43] 123 1.64 [1.15–2.34] 202 1.41 [1.01–1.96]
Nonpersistence
Risk of
30-day
gap in
treatment
54 321 (14 800) 688 Reference 605 1.07 [0.96–1.20] 3418 1.45 [1.33–1.59] 10 089 1.22 [1.12–1.33]
HR indicates hazard ratio; IQR, interquartile range.
Table 4. Number and Percentage of First-Time Switchers
Initiation OAC Group
Switch to (Row %)
Apixaban Rivaroxaban Dabigatran Warfarin
Total No. of Switchers
(% of Total Initiated)
Apixaban (n=7963) — 93 (22) 63 (15) 270 (63) 426 (5)
Rivaroxaban (n=6715) 182 (27) — 198 (29) 305 (45) 685 (10)
Dabigatran (n=15 413) 550 (20) 703 (26) — 1495 (54) 2748 (19)
Warfarin (n=24 230) 564 (20) 758 (28) 1430 (52) — 2752 (11)
OAC indicates oral anticoagulant.
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bleeding with low-dose dabigatran). Our ﬁnding may be
inﬂuenced by unmeasured confounders or selection bias: For
example, dabigatran 110 mg BID users were, on average,
>14 years older and had higher HAS-BLED (2.5 vs 1.8) than
dabigatran 150 mg BID users. When restricting the analyses
to patients aged <80 years (ie, excluding patients where only
low dosage is recommended), we found no differences in
major bleeding risk using apixaban as reference. Thus,
prescribing physicians may systematically select patient for
lower dosages because of perceived (and possibly correctly)
increased bleeding risk, which is reﬂected in the observed
higher bleeding rates in the dabigatran 110 mg group. Studies
investigating potential physician preferences and prescription
patterns according to dosages are most welcome. In the
clinical trials, discontinuation risk was lower for apixaban
(2310 of 9088 [25.4%] vs 2493 of 9052 [27.5%] patients), but
higher for rivaroxaban (23.7% vs 22.2%) and dabigatran (14.5–
15.5% vs 10.2%) compared with warfarin. In our study, the
cumulative incidence curve of nonpersistence (Figure 4)
showed better persistence to the NOACs than to warfarin.
Although deﬁnitions of persistence between the trials and the
present study are not readily comparable, it is reassuring that
these new agents seem to yield persistence in 70% to 85% of
patients after 3 years; this is considerably higher than the
40% observed for warfarin. However, it should be recognized
that the method used is based on prescription claims.
Following the initiation of treatment, some treatment
episodes last longer (warfarin and rivaroxaban), attributed to
differences in pack sizes, and this likely affect the results.
Notably, ﬁndings from our landmark analyses suggest that
warfarin users initially had very good persistence, but when
looking beyond the ﬁrst 90 days, we found, from the
cumulative incidence and the adjusted Cox model, higher
persistence for apixaban and rivaroxaban and lower for
dabigatran and warfarin. The fact that gastrointestinal side
effects have frequently been reported in dabigatran users
could potentially be a mechanism behind our ﬁnding that
dabigatran users were more likely to be nonpersistent
Figure 3. Cumulative incidence of major bleeding according to OAC treatment. Cumulative incidence of
major bleeding according to OAC treatment (nonswitch patients only) taking into account competing of
death. OAC indicates oral anticoagulant.
Table 6. Distribution and Type of Major Bleeding
Type of Major Bleeding No. (%)
Intracranial 399 (17)
Gastrointestinal 1022 (42)
Respiratory 276 (11)
Pericardial 16 (1)
Ocular 19 (1)
Renal/urinary 454 (19)
Anemia 232 (10)
Total 2418 (100)
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compared with apixaban users.19,24 Several compliance
studies have shown that persistence to treatment is strongly
affected by the number of tablets taken daily.25 Perhaps
surprisingly, our data suggested that rivaroxaban (given OD)
users did not have lower risk of nonpersistence compared
with apixaban users (given BID). Periods off treatment are very
Table 7. Sex-Stratiﬁed Analyses of Risk of Major Bleeding and Nonpersistence
Population
(Total No.
of Events)
Apixaban Rivaroxaban Dabigatran Warfarin
No.
Events HR [95% CI]
No.
Events HR [95% CI]
No.
Events HR [95% CI]
No.
Events HR [95% CI]
Major bleeding
Total major
bleeding (Female)
23 883 (966) 102 Reference 133 1.47 [1.12–1.91] 308 1.45 [1.13–1.85] 423 1.46 [1.14–1.86]
Total major
bleeding (Male)
30 438 (1452) 150 Reference 210 1.51 [1.22–1.88] 387 1.01 [0.82–1.24] 705 1.08 [0.89–1.32]
30-day major
bleeding (Female)
23 883 (182) 18 Reference 32 2.31 [1.29–4.15] 49 2.15 [1.20–3.86] 83 2.06 [1.19–3.57]
30-day major
bleeding (Male)
30 438 (266) 34 Reference 39 1.35 [0.85–2.16] 74 1.36 [0.87–2.14] 119 1.08 [0.71–1.64]
Nonpersistence
Risk of 30 day
gap in treatment
(female)
23 883 (6226) 260 Reference 235 1.10 [0.92–1.32] 1307 1.64 [1.43–1.89] 4424 1.66 [1.45–1.90]
Risk of 30-day
gap in treatment
(male)
30 438 (8574) 428 Reference 370 1.05 [0.91–1.20] 2111 1.32 [1.18–1.47] 5665 0.97 [0.88–1.08]
HR indicates hazard ratio.
Figure 4. Cumulative incidence of nonpersistence according to OAC treatment. Cumulative incidence of
nonpersistence (deﬁned as more than a 30-day gap in treatment) according to OAC treatment (nonswitch
patients only) taking into account competing of death. OAC indicates oral anticoagulant.
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worrisome given short half-life elimination (range, 10–17
hours) and may place patients at markedly increased
thromboembolic risk.26 The degree of suboptimal protection
needs to be investigated further as well as any markers of
interruption of treatment.
Do these data aid in the selection of OAC for the practicing
clinician and patients? We found highest persistence to
apixaban and rivaroxaban, fewer major bleeding complications
with apixaban overall, and some evidence that women taking
dabigatran and warfarin may be at further increased risk of
major bleeding compared to men. Even though causality is a
challenge in observational data, these ﬁndings warrant
attention. Our ﬁndings suggest that, in a real-life clinical
setting, uptake and safety issues differ between NOACs.
Clariﬁcation for health care providers and patients will require
future observational studies with information on prescription
patterns (including sex differences) and assessment of
effectiveness, given that randomization between NOACs
seems unimaginable at the moment.
Limitations
Despite providing updated and real-life data on experience
from OAC use, our study is limited by its observational nature.
The Danish population consists of a racially homogeneous
population of mainly whites, which makes extrapolation of the
results to other populations limited. Although indications of
use should be similar across the different OAC cohorts in our
study, the potential for selection bias should be recognized.
Concerning unmeasured confounders, we did not have
information on left ventricle ejection fraction, on tobacco
use, degree of potential renal dysfunction, body mass index,
or patient and physician preferences. Our deﬁnition of major
bleeding includes all episodes requiring hospitalization; and
hospital databases have shown high precision for registration
of bleeding events.27 The diagnostic coding for AF has
previously been validated with high positive predictive value
(97%).28 Also, our analyses do not take local or regional
recommendations or policies of ﬁrst-line OAC use into
Table 8. Risk of Major Bleeding and Nonpersistence Following Full NOAC Availability and According to Switch Status
Population
(Total No.
of Events)
Apixaban Rivaroxaban Dabigatran Warfarin
No.
Events HR [95% CI]
No.
Events HR [95% CI]
No.
Events HR [95% CI] No. Events HR [95% CI]
Major bleeding*
Total major
bleeding
(debut apixaban)
36 762 (1427) 244 Reference 283 1.48 [1.24–1.76] 337 1.15 [0.96–1.37] 563 1.23 [1.04–1.45]
30-day major
bleeding
(debut apixaban)
36 762 (312) 52 Reference 65 1.66 [1.15–2.40] 70 1.53 [1.04–2.24] 125 1.45 [1.03–2.04]
Total major
bleeding
(OAC nonswitch)
54 321 (2180) 221 Reference 280 1.49 [1.25–1.79] 612 1.13 [0.95–1.34] 1067 1.21 [1.02–1.42]
30-day
major bleeding
(OAC nonswitch)
54 321 (440) 51 Reference 70 1.73 [1.20–2.49] 118 1.62 [1.13–2.32] 201 1.42 [1.02–1.99]
Total major
bleeding
(OAC switch)
6611 (238) 31 Reference 63 1.51 [0.98–2.34] 83 1.47 [0.95–2.29] 61 1.25 [0.80–1.97]
Nonpersistence
Risk of 30-day
gap in treatment
(debut apixaban)
36 762 (6921) 683 Reference 505 1.02 [0.91–1.15] 1756 1.50 [1.37–1.65] 3977 1.20 [1.10–1.30]
Risk of 30-day
gap in treatment
(OAC nonswitch)
54 321 (14 597) 664 Reference 579 1.07 [0.96–1.20] 3371 1.45 [1.32–1.58] 9983 1.22 [1.12–1.33]
Risk of 30-day
gap in treatment
(OAC switch)
1001 (203) 24 Reference 26 1.01 [0.58–1.77] 47 1.97 [1.16–3.33] 106 1.13 [0.71–1.80]
HR indicates hazard ratio; NOAC, nonvitamin K antagonist oral anticoagulant; OAC, oral anticoagulant.
*Too few events to assess 30-day major bleeding risk in OAC switch patients.
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account. We conﬁrm data from a previous study that the
proportions initiating OAC treatment change over time
(dabigatran and warfarin initiation declined, whereas apixaban
and rivaroxaban increased).29 The decline of warfarin use is
most likely explained by increased NOAC use, whereas the
decline in dabigatran partly can be explained that elderly is
less likely to be initiated.29,30 The observation period of
especially apixaban was shorter compared to the other
cohorts attributed to later entrance to market. The possibility
exists that treatment courses that span multiple prescriptions
claims might be subject to more episodes off treatment.
However, we do not believe this would strongly affect our
ﬁndings given that we took the switch to another OAC into
account (and also performed analyses with censoring at time
of switch), performed sensitivity analyses in the period when
all NOACs were available, and used methods that allowed for
continuous exposure assessment. All prescriptions of OAC are
captured by the databases, but our method used to deﬁne
OAC exposure is an approximation. Given that actual intake of
tablets is unknown (data based on prescription claims) and
likely to be closely related to a recent prescription claim, this
could have affected our ﬁndings. However, because there is
only partial reimbursement of drug expenses in Denmark,
patient copayment would indicate an intention to take the
claimed prescription. Furthermore, given that analyses of
shorter-term major bleeding risk (within 30 days) are consis-
tent with results from the total follow-up period, we believe
our method to be valid in assessing an association between
OAC exposure and bleeding.
Conclusions
In a contemporary real-life cohort of nonvalvular AF patients,
differences in major bleeding complications and persistence
between OAC therapies exist. Apixaban had lower 30-day and
total major bleeding risk compared to rivaroxaban, dabigatran,
and warfarin. Nonpersistence was highest for dabigatran and
warfarin, compared to apixaban and rivaroxaban. Given that
the landscape of stroke prevention in AF is rapidly evolving,
results from nonrandomized studies of potential safety issues
need to come to the attention to patients and health care
providers. As more real-world data on NOACs accumulate,
future studies should also focus on effectiveness to help
inform optimal treatment decisions.
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